Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AbobotulinumtoxinA (Espad Pharmed) for Glabellar Lines
NCT06946160Phase 3Completed
- Sponsor
- Espad Pharmed
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in glabellar lines (2 arms), sponsored by Espad Pharmed. Primary endpoint: Percentage of responders at maximum frown by investigator's assessment at Day 30. Started May 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT06946160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946160.